Tom Wei-Wu Chen
@saxotomy
Followers
999
Following
2K
Media
147
Statuses
1K
Dedicated sarcoma and breast medical oncologist from Taiwan. (National Taiwan University Hospital and Cancer Center)
Taiwan
Joined April 2010
Thank you @tompowles1 for hosting me. It was a pleasure
🆕podcast🎧: @tompowles1 and @ZerAlona discuss the latest @myESMO Clinical Practice Guideline on early and locally advanced #NSCLC
https://t.co/VcZqUvgHTs
0
1
2
⚾ REPOST TO WIN ⚾ We’re giving away a signed Josh Naylor baseball and all you need to do is hit that repost button to enter.
82
5K
3K
The ATLAS–ESMO session Panel discussion has just started with Dr. Yonemori, Dr. Kato, Dr. Nuttapong, and Dr. Sjoukje Oosting.
0
1
2
1
3
15
SFA is proud to share the new Pushing Ultra-Rare Sarcomas Beyond Hope (PUSH) website. SFA is the administrator of this global collaboration, which brings together clinicians, scientists, and patient advocates working to accelerate research and improve care for people with
0
2
3
The ATLAS–ESMO session Dr. Kato will give an overview of the epidemiology and biology of key GI cancers in Asia Pacific, and summarize ongoing collaborative clinical research, highlighting current challenges and future opportunities.
0
1
4
FORTRESS and FORTIFY scientific program for the 2026 workshop in Leuven (BE) shared with our registered attendees today. https://t.co/SSr7ZwiUbK. We are fully booked!
kuleuven.be
FORTRESS is a scientific initiative by the University Hospitals (UZ Leuven) of KU Leuven (Belgium) and the West German Cancer Center, University of Duisburg/Essen (Germany), an annual academic...
0
2
8
OMG 😱 Scientific evidence demonstrate that RT-induced abscopal effect does NOT exist 👇🏼👇🏼👇🏼
A new Nature paper just delivered a shock to a long-lived oncology myth. 🔗 https://t.co/JMaFE9Ezco For years we’ve been told that radiotherapy—and its cousins like SBRT, TARE, Y-90—might trigger the “abscopal effect,” a systemic immune response that helps control distant
2
12
30
Exercise as anti-cancer medicine (“Exercizumab”) @Cancer_Cell
https://t.co/51bb4qGQfY
@JCO_ASCO
https://t.co/tBcD44WuML
12
300
946
How to treat #DFSP? We explore the #treatment options as well as #clinicaltrials in our #review article! @AMCzarnecka @reininsarcoma @ItaSarcomaGroup @sarcomapatients @ChirSarcomi_INT @rutkowskip1972 @SpringerNature @NCN_PL @NIO_PIB @NCCN
https://t.co/X5FpjAZYgx
0
1
6
Belzutifan for Advanced Pheochromocytoma or Paraganglioma | New England Journal of Medicine
nejm.org
Pheochromocytoma and paraganglioma are neoplasms originating in the adrenal medulla and extraadrenal paraganglia, respectively. Most cases of metastatic pheochromocytoma and paraganglioma are drive...
1
7
19
🚨Historical presentation at #CTOS2025 ChonDRAgon - first positive randomised trial in chondrosarcoma 🔹Ozekibart vs placebo 🔹 mPFS 5.52 vs 2.66 months 🔹 HR 0.479; p<0.0001 🔹 a manageable safety profile - most common TRAE: fatigue, diarrhea, and nausea
0
4
19
Inspiring Day at @ctosociety for TARPSWG Semi-Annual Meeting 2025 - Alessandro Gronchi (@alegronchi) https://t.co/esMiIlyvHU
#OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #CTOS #CTOS2025 #TARPSWG
0
1
8
Deeply honored to receive the Brian Van Tine Memorial Peer Recognition Award for Excellence in LMS Research from the @NationalLMSF presented at #CTOS2025 @ctosociety I am grateful to the entire LMS Roundtable community & Mitch and Annie Achee for their unwavering support.
2
7
34
#StandingCommittees meeting of @ctosociety at #CTOS2025. Dedicated members helping to shape our society and cater for our members. We are looking for more members to join! Find out more at https://t.co/cQRtUG49KW and contact committee chairs for more info!
0
6
23
What makes dedifferentiated liposarcoma dedifferentiated? Important insights from new @DanaFarber sarcoma faculty Dr. Erica Pimenta. Another area for GLP1 research? #CTOS2025
0
10
28
RT associated #angiosarcoma of the breast/chest wall “debate”. “See five experts get six different opinions”. Management guided by strong belief and little data. To be continued at the next meetings…. #CTOS2025
0
5
21
The first international analysis of spindle-cell/sclerosing rhabdomyosarcoma (S-RMS) shows: 🔹 1/3 of localized S-RMS can be cured after complete surgery 🔹 Local ≫ distant relapse → need for better loco-regional control 🔹 Advanced disease: median OS ≈ 15 mo, 2-yr OS ≈ 25%
0
4
11
Promising data for VT3989, a selective multi-TEAD inhibitor targeting Hippo/YAP signaling. In the Phase I/II study, VT3989 showed: 🔹 Favorable safety — mostly Grade 1–2 TRAEs 🔹 Objective responses in advanced EHE 🔹 Durable PR > 9 months in 1 pt #CTOS2025 @candace_haddox
0
14
24